For the quarter ended March 2026, TransMedics (TMDX Quick QuoteTMDX - Free Report) reported revenue of $173.93 million, up 21.2% over the same period last year. EPS came in at $0.30, compared to $0.70 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $175.67 million, representing a surprise of -0.99%. The company delivered an EPS surprise of -51.46%, with the consensus EPS estimate being $0.62.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how TransMedics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• OCS transplant revenue- United States- Total: $167.02 million versus the three-analyst average estimate of $171.27 million. The reported number represents a year-over-year change of +20.5%.
• OCS transplant revenue- United States- Lung total revenue: $2.2 million versus the three-analyst average estimate of $4.6 million.
• OCS transplant revenue- United States- Heart total revenue: $25.86 million versus the three-analyst average estimate of $31.3 million.
• OCS transplant revenue- All other countries- Heart total revenue: $5.01 million versus $3.78 million estimated by three analysts on average.
• OCS transplant revenue- All other countries- Total: $5.65 million versus $4.45 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +38.9% change.
• OCS transplant revenue- All other countries- Lung total revenue: $0.63 million versus $0.4 million estimated by three analysts on average.
• OCS transplant revenue- United States- Liver total revenue: $138.97 million versus the three-analyst average estimate of $135.37 million.
• OCS transplant revenue- Lung net revenue (U.S. & All Other countries): $2.82 million versus $5 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -29.6% change.
• OCS transplant revenue- Heart net revenue (U.S. & All Other countries): $30.87 million versus $35.08 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +3.5% change.
• OCS transplant revenue- Liver net revenue (U.S. & All Other countries): $138.98 million compared to the $135.64 million average estimate based on three analysts. The reported number represents a change of +27.7% year over year.
• Revenue- Net Product: $107.97 million versus $105.26 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +22.4% change.
• Revenue- Service: $65.96 million versus $65.1 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +19.3% change.

View all Key Company Metrics for TransMedics here>>>

Shares of TransMedics have returned -7.4% over the past month versus the Zacks S&P 500 composite's +9.5% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.